Abstract
Abnormalities of chromosome 1q21 are common in B cell malignancies, but their target genes are largely unknown. By cloning the breakpoints of a (1;14) (q21;q32) chromosomal translocation in a myeloma cell line, we have identified two novel genes, IRTA1 and IRTA2, encoding cell surface receptors homologous to the Fc and inhibitory receptor families. Both genes are selectively expressed in mature B cells: IRTA1 in marginal zone B cells and IRTA2 in centrocytes, marginal zone B cells, and immunoblasts. As a result of the t(1;14), IRTA1 is fused to the immunoglobulin Cα domain to produce a chimeric IRTA1/Cα fusion protein. In tumor cell lines with 1q21 abnormalities, IRTA2 expression is deregulated. Thus, IRTA1 and IRTA2 are novel immunoreceptors implicated in B cell development and lymphomagenesis.
| Original language | English |
|---|---|
| Pages (from-to) | 277-289 |
| Number of pages | 13 |
| Journal | Immunity |
| Volume | 14 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2001 |
Fingerprint
ASJC Scopus subject areas
- Immunology and Allergy
- Infectious Diseases
- Immunology
Cite this
IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy. / Hatzivassiliou, Georgia; Miller, Ira; Takizawa, Jun; Palanisamy, Nallasivam; Rao, Pulivarthi H.; Iida, Shinsuke; Tagawa, Shinichi; Taniwaki, Masafumi; Russo, James; Neri, Antonino; Cattoretti, Giorgio; Clynes, Raphael; Mendelsohn, Cathy; Chaganti, R. S K; Dalla-Favera, Riccardo.
In: Immunity, Vol. 14, No. 3, 2001, p. 277-289.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy
AU - Hatzivassiliou, Georgia
AU - Miller, Ira
AU - Takizawa, Jun
AU - Palanisamy, Nallasivam
AU - Rao, Pulivarthi H.
AU - Iida, Shinsuke
AU - Tagawa, Shinichi
AU - Taniwaki, Masafumi
AU - Russo, James
AU - Neri, Antonino
AU - Cattoretti, Giorgio
AU - Clynes, Raphael
AU - Mendelsohn, Cathy
AU - Chaganti, R. S K
AU - Dalla-Favera, Riccardo
PY - 2001
Y1 - 2001
N2 - Abnormalities of chromosome 1q21 are common in B cell malignancies, but their target genes are largely unknown. By cloning the breakpoints of a (1;14) (q21;q32) chromosomal translocation in a myeloma cell line, we have identified two novel genes, IRTA1 and IRTA2, encoding cell surface receptors homologous to the Fc and inhibitory receptor families. Both genes are selectively expressed in mature B cells: IRTA1 in marginal zone B cells and IRTA2 in centrocytes, marginal zone B cells, and immunoblasts. As a result of the t(1;14), IRTA1 is fused to the immunoglobulin Cα domain to produce a chimeric IRTA1/Cα fusion protein. In tumor cell lines with 1q21 abnormalities, IRTA2 expression is deregulated. Thus, IRTA1 and IRTA2 are novel immunoreceptors implicated in B cell development and lymphomagenesis.
AB - Abnormalities of chromosome 1q21 are common in B cell malignancies, but their target genes are largely unknown. By cloning the breakpoints of a (1;14) (q21;q32) chromosomal translocation in a myeloma cell line, we have identified two novel genes, IRTA1 and IRTA2, encoding cell surface receptors homologous to the Fc and inhibitory receptor families. Both genes are selectively expressed in mature B cells: IRTA1 in marginal zone B cells and IRTA2 in centrocytes, marginal zone B cells, and immunoblasts. As a result of the t(1;14), IRTA1 is fused to the immunoglobulin Cα domain to produce a chimeric IRTA1/Cα fusion protein. In tumor cell lines with 1q21 abnormalities, IRTA2 expression is deregulated. Thus, IRTA1 and IRTA2 are novel immunoreceptors implicated in B cell development and lymphomagenesis.
UR - http://www.scopus.com/inward/record.url?scp=17744386928&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=17744386928&partnerID=8YFLogxK
U2 - 10.1016/S1074-7613(01)00109-1
DO - 10.1016/S1074-7613(01)00109-1
M3 - Article
C2 - 11290337
AN - SCOPUS:17744386928
VL - 14
SP - 277
EP - 289
JO - Immunity
JF - Immunity
SN - 1074-7613
IS - 3
ER -